(Total Views: 223)
Posted On: 11/14/2019 12:04:36 PM
Post# of 36542
They definitely do. That appraisal was 8 years ago. AE37 was targeting a larger market than the one for Herceptin. AE37 didn’t succeed in the overall Phase II, but did succeed in a subgroup (triple neg). That’s an important and valuable market, but a smaller one than anticipated in 2011. Yes, with new combinational studies the overall market for AE37 can grow significantly, but they aren’t conducting those studies yet.
“The report defined fair value as the price at which an asset or liability could be exchanged in a current transaction between knowledgeable, unrelated willing parties, and arrived at a value of $300 million. Willing parties are presumed to be marketplace participants representing unrelated buyers and sellers. Given that Herceptin, which is only available to treat roughly one-third of the patients that would be eligible for AE37, had sales of $1.8 Billion in 2008, the Company believes this estimate to be conservative.”
https://www.prnewswire.com/news-releases/gene...62484.html
“The report defined fair value as the price at which an asset or liability could be exchanged in a current transaction between knowledgeable, unrelated willing parties, and arrived at a value of $300 million. Willing parties are presumed to be marketplace participants representing unrelated buyers and sellers. Given that Herceptin, which is only available to treat roughly one-third of the patients that would be eligible for AE37, had sales of $1.8 Billion in 2008, the Company believes this estimate to be conservative.”
https://www.prnewswire.com/news-releases/gene...62484.html
(2)
(0)Scroll down for more posts ▼
